These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 12147908)

  • 1. Imipenem.
    Locham KK; Sodhi M; Sarwal D
    Indian Pediatr; 2002 Jul; 39(7):703; author reply 703-4. PubMed ID: 12147908
    [No Abstract]   [Full Text] [Related]  

  • 2. Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program.
    Turner PJ
    Diagn Microbiol Infect Dis; 2006 Nov; 56(3):341-4. PubMed ID: 17049798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.
    Ong CT; Tessier PR; Li C; Nightingale CH; Nicolau DP
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):153-61. PubMed ID: 16930925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic-pharmacodynamic modeling of electroencephalogram effect of imipenem in rats with acute renal failure.
    Dupuis A; Limosin A; Paquereau J; Mimoz O; Couet W; Bouquet S
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3607-9. PubMed ID: 11709350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transduction of imipenem resistance by wild-type bacteriophages carried by three strains of Pseudomonas aeruginosa isolated from a single source.
    Blahová J; Králiková K; Krcméry V; Mlynarcík D; Trupl J
    J Antimicrob Chemother; 1998 Jun; 41(6):660-2. PubMed ID: 9687107
    [No Abstract]   [Full Text] [Related]  

  • 6. Role of outer membrane protein OprD and penicillin-binding proteins in resistance of Pseudomonas aeruginosa to imipenem and meropenem.
    Farra A; Islam S; Strålfors A; Sörberg M; Wretlind B
    Int J Antimicrob Agents; 2008 May; 31(5):427-33. PubMed ID: 18375104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation.
    Lomaestro BM; Drusano GL
    Antimicrob Agents Chemother; 2005 Jan; 49(1):461-3. PubMed ID: 15616337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel insertion sequence, ISPA26, in oprD of Pseudomonas aeruginosa is associated with carbapenem resistance.
    Evans JC; Segal H
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3776-7. PubMed ID: 17682099
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic modelling of the electroencephalogram effect of imipenem in rats with experimental hypovolaemia or endotoxaemia.
    Limosin A; Dupuis A; Lamarche I; Mimoz O; Paquereau J; Couet W
    J Antimicrob Chemother; 2004 Jul; 54(1):187-92. PubMed ID: 15163649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pharmacodynamic model for the action of the antibiotic imipenem on Pseudomonas aeruginosa populations in vitro.
    Berg PH; Voit EO; White RL
    Bull Math Biol; 1996 Sep; 58(5):923-38. PubMed ID: 8837524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance of Pseudomonas aeruginosa to imipenem is independent of beta-lactamase production.
    Büscher KH; Cullmann W; Opferkuch W
    J Antimicrob Chemother; 1987 May; 19(5):700-1. PubMed ID: 3112097
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacodynamic determinants of imipenem's efficacy in a man-adapted animal model.
    Flückiger U; Gerber AU; Segessenmann C; Bangerter T
    J Chemother; 1989 Jul; 1(4 Suppl):60-1. PubMed ID: 16312304
    [No Abstract]   [Full Text] [Related]  

  • 13. Evolution of an integron carrying blaVIM-2 in Eastern Europe: report from the SENTRY Antimicrobial Surveillance Program.
    Walsh TR; Toleman MA; Hryniewicz W; Bennett PM; Jones RN
    J Antimicrob Chemother; 2003 Jul; 52(1):116-9. PubMed ID: 12805257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
    Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
    Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem.
    Sakyo S; Tomita H; Tanimoto K; Fujimoto S; Ike Y
    J Antibiot (Tokyo); 2006 Apr; 59(4):220-8. PubMed ID: 16830889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The postantibiotic effect of imipenem.
    Manek N; Andrews JM; Wise R
    J Antimicrob Chemother; 1986 Nov; 18(5):641. PubMed ID: 3100488
    [No Abstract]   [Full Text] [Related]  

  • 17. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates.
    El Amin N; Giske CG; Jalal S; Keijser B; Kronvall G; Wretlind B
    APMIS; 2005 Mar; 113(3):187-96. PubMed ID: 15799762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to imipenem and zinc in clinical isolates of Pseudomonas aeruginosa.
    Velasco C; Rodríguez JM; Conejo MC; Pascual A
    Int J Antimicrob Agents; 2006 Oct; 28(4):377-8. PubMed ID: 16965905
    [No Abstract]   [Full Text] [Related]  

  • 19. Prevalence of multi and pan drug resistant Pseudomonas aeruginosa with respect to ESBL and MBL in a tertiary care hospital.
    Jayakumar S; Appalaraju B
    Indian J Pathol Microbiol; 2007 Oct; 50(4):922-5. PubMed ID: 18306607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increase of imipenem resistance among Pseudomonas aeruginosa isolates from a Polish paediatric hospital (1993-2002).
    Patzer JA; Dzierzanowska D
    Int J Antimicrob Agents; 2007 Feb; 29(2):153-8. PubMed ID: 17157481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.